FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for Bicara Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings per share of ($2.12) for the year, down from their previous forecast of ($1.61). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.89) per share.

Other research analysts have also issued research reports about the company. Morgan Stanley began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price on the stock. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price on the stock. TD Cowen began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.33.

Bicara Therapeutics Price Performance

NASDAQ:BCAX opened at $20.17 on Monday. Bicara Therapeutics has a one year low of $18.33 and a one year high of $28.09. The stock has a 50-day moving average price of $23.33.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14).

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cinctive Capital Management LP purchased a new position in shares of Bicara Therapeutics during the third quarter valued at $229,000. Barclays PLC purchased a new stake in Bicara Therapeutics in the 3rd quarter worth about $255,000. Jane Street Group LLC purchased a new position in Bicara Therapeutics during the 3rd quarter valued at about $309,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at about $462,000. Finally, Soros Fund Management LLC purchased a new stake in shares of Bicara Therapeutics in the third quarter worth approximately $509,000.

Insider Buying and Selling at Bicara Therapeutics

In related news, major shareholder James E. Flynn bought 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the transaction, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ra Capital Management, L.P. bought 1,833,000 shares of Bicara Therapeutics stock in a transaction dated Monday, September 16th. The shares were bought at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.